138 related articles for article (PubMed ID: 26898266)
41. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study.
Holowiecki J; Krawczyk-Kulis M; Giebel S; Jagoda K; Stella-Holowiecka B; Piatkowska-Jakubas B; Paluszewska M; Seferynska I; Lewandowski K; Kielbinski M; Czyz A; Balana-Nowak A; Król M; Skotnicki AB; Jedrzejczak WW; Warzocha K; Lange A; Hellmann A
Br J Haematol; 2008 Jun; 142(2):227-37. PubMed ID: 18492099
[TBL] [Abstract][Full Text] [Related]
42. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
43. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
45. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
46. Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
Pan X; Nariai N; Fukuhara N; Saito S; Sato Y; Katsuoka F; Kojima K; Kuroki Y; Danjoh I; Saito R; Hasegawa S; Okitsu Y; Kondo A; Onishi Y; Nagami F; Kiyomoto H; Hozawa A; Fuse N; Nagasaki M; Shimizu R; Yasuda J; Harigae H; Yamamoto M
Br J Haematol; 2017 Jan; 176(2):318-321. PubMed ID: 26822323
[No Abstract] [Full Text] [Related]
47. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
48. Immunoglobulin gene rearrangement in detection of minimal residual disease in acute lymphoblastic leukaemia.
Nayyar A; Ahmed S
J Ayub Med Coll Abbottabad; 2013; 25(1-2):159-61. PubMed ID: 25098084
[TBL] [Abstract][Full Text] [Related]
49. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
50. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease.
van der Velden VH; Szczepanski T; Wijkhuijs JM; Hart PG; Hoogeveen PG; Hop WC; van Wering ER; van Dongen JJ
Leukemia; 2003 Sep; 17(9):1834-44. PubMed ID: 12970784
[TBL] [Abstract][Full Text] [Related]
51. CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies.
Halper-Stromberg E; McCall CM; Haley LM; Lin MT; Vogt S; Gocke CD; Eshleman JR; Stevens W; Martinson NA; Epeldegui M; Holdhoff M; Bettegowda C; Glantz MJ; Ambinder RF; Xian RR
Clin Chem; 2021 Nov; 67(11):1524-1533. PubMed ID: 34491318
[TBL] [Abstract][Full Text] [Related]
52. ClonoSEQ assay for the detection of lymphoid malignancies.
Monter A; Nomdedéu JF
Expert Rev Mol Diagn; 2019 Jul; 19(7):571-578. PubMed ID: 31179776
[No Abstract] [Full Text] [Related]
53. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
[TBL] [Abstract][Full Text] [Related]
54. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
55. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
56. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
57. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
[No Abstract] [Full Text] [Related]
58. Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia.
Della Starza I; Nunes V; Cavalli M; De Novi LA; Ilari C; Apicella V; Vitale A; Testi AM; Del Giudice I; Chiaretti S; Foà R; Guarini A
Br J Haematol; 2016 Aug; 174(4):541-9. PubMed ID: 27172403
[TBL] [Abstract][Full Text] [Related]
59. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.
Evans PA; Short MA; Owen RG; Jack AS; Forsyth PD; Shiach CR; Kinsey S; Morgan GJ
J Clin Oncol; 1998 Nov; 16(11):3616-27. PubMed ID: 9817283
[TBL] [Abstract][Full Text] [Related]
60. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]